Prescient Therapeutics (ASX:PTX) partners with MD Anderson Cancer Center
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class,...
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class,...
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce...
Prescient Therapeutics (PTX) advanced multiple clinical programs for its targeted and cell therapy drugs over...
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune...
Prescient Therapeutics (PTX) has opened patient enrolments for an expanded phase 1B trial of its...
Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs...
Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell &...
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage...
Prescient Therapeutics (PTX) is progressing the trial of its cancer-blocking drug PTX100 following successful results...
Prescient Therapeutics (PTX) says recent results from testing show its entire platform has been substantially...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.